06:47:44 Europe / Stockholm

Attachments

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2024-11-20 Quarterly Report 2024-Q3
2024-09-04 Extra General Meeting 2024
2024-08-28 Quarterly Report 2024-Q2
2024-05-28 Quarterly Report 2024-Q1
2024-05-15 Ex-date Ordinary Dividend ISAB 0.00 SEK
2024-05-14 Annual General meeting
2024-02-28 Year-end Report 2023
2023-11-22 Quarterly Report 2023-Q3
2023-08-29 Quarterly Report 2023-Q2
2023-05-31 Quarterly Report 2023-Q1
2023-05-15 Ex-date Ordinary Dividend ISAB 0.00 SEK
2023-05-12 Annual General meeting
2023-02-28 Year-end Report 2022
2022-11-22 Quarterly Report 2022-Q3
2022-08-29 Quarterly Report 2022-Q2
2022-06-08 Ex-date Ordinary Dividend ISAB 0.00 SEK
2022-05-23 Quarterly Report 2022-Q1
2022-05-06 Annual General meeting
2022-02-28 Year-end Report 2021
2021-11-24 Quarterly Report 2021-Q3
2021-08-26 Quarterly Report 2021-Q2
2021-06-22 Extra General Meeting 2021
2021-06-09 Ex-date Ordinary Dividend ISAB 0.00 SEK
2021-06-08 Annual General meeting
2021-05-19 Quarterly Report 2021-Q1
2021-02-25 Year-end Report 2020
2020-11-26 Quarterly Report 2020-Q3
2020-08-26 Quarterly Report 2020-Q2
2020-06-12 Extra General Meeting 2020
2020-05-13 Ex-date Ordinary Dividend ISAB 0.00 SEK
2020-05-12 Annual General meeting
2020-05-07 Quarterly Report 2020-Q1
2020-02-20 Year-end Report 2019
2019-11-14 Quarterly Report 2019-Q3
2019-08-22 Quarterly Report 2019-Q2
2019-05-22 Annual General meeting
2019-05-16 Quarterly Report 2019-Q1
2019-05-10 Ex-date Ordinary Dividend ISAB 0.00 SEK
2019-02-21 Year-end Report 2018
2018-12-13 Extra General Meeting 2018
2018-11-15 Quarterly Report 2018-Q3
2018-08-22 Quarterly Report 2018-Q2
2018-05-24 Ex-date Ordinary Dividend ISAB 0.00 SEK
2018-05-23 Annual General meeting
2018-05-16 Quarterly Report 2018-Q1
2018-02-22 Year-end Report 2017
2017-11-17 Quarterly Report 2017-Q3
2017-08-28 Quarterly Report 2017-Q2

Description

CountrySweden
ListSpotlight
SectorHealth care
IndustryMedical technology
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2023-11-13 08:30:00

(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB's aerosol generating platform PreciseInhale and its unique cell exposure module.

The returning client is a loyal customer and has long been a keen advocate of ISAB's unique multi-modular, precision dosing aerosol system PreciseInhale. Within inhalation the customer has an extensive, competitive portfolio and robust pipeline.

PreciseInhale - reducing risk and costs

PreciseInhale is unique within inhaled drug development as a `precision dosing' system. Unlike standard `tower testing' systems, it customizes the individual aerosol dose to individual test animals. This achieves exceptionally high-precision and predictive data in the preclinical stages, so reducing risk and costs in later clinical stages.

Leading the way in in vitro testing

The advantages of in vitro testing are becoming increasingly understood in inhalation drug development. In vitro dissolution methods like the ones designed by ISAB can generate predictive IVIVC (in vitro in vivo correlated) data early on that enable poor Drug Candidates to be eliminated, reducing costs and accelerating development.

CEO Manoush Masarrat: "it is a great validation when an existing customer returns once again. This time to purchase another main platform system and a new test module. We are grateful for their continued confidence in our products - and proud that our technology has made a positive contribution to their impressive inhalation portfolio"